Physician profile
John Y Kim
NPI 1467442384
$339,124.52
in general payments reported to CMS, 2019-2025
47 companies · $115K in 2025
The $115K reported for 2025 was more than what 98% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,281 · 2020: $7,005 · 2021: $9,458 · 2022: $22K · 2023: $65K · 2024: $116K · 2025: $115K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $229K · Travel and Lodging: $34K · Food and Beverage: $17K · Consulting Fee: $14K · Education: $219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $229,404.85 |
| Travel and Lodging | $34,384.41 |
| Food and Beverage | $17,067.56 |
| Consulting Fee | $14,015.34 |
| Education | $219.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $231,964.05 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $61,337.03 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $11,046.19 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $7,464.97 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $7,094.87 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Pfizer INC. | $7,004.00 | 2019-2025 | |
| Optinose US, INC. | $3,992.37 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,837.23 | 2019-2023 | Airduo Digihaler |
| Csl Behring | $899.29 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Genentech USA, INC. | $761.08 | 2019-2025 | Xolair |
| Kaleo, INC. | $701.66 | 2019-2024 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $631.91 | 2020-2025 | Hyqvia, Takhzyro, Cuvitru |
| Grifols USA, LLC | $565.82 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Pharming Healthcare, INC. | $404.43 | 2019-2025 | Ruconest |
| Abbvie INC. | $362.30 | 2022-2025 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $324.29 | 2022-2025 | Tezspire, Actimmune |
| Covis Pharma Gmbh | $248.48 | 2019-2022 | |
| Bio Products Laboratory USA, INC. | $246.30 | 2019-2023 | Gammaplex, Coagadex |
| Sanofi-Aventis U.S. LLC | $235.26 | 2021-2025 | |
| Biocryst US Sales Co., LLC | $221.64 | 2021-2025 | Orladeyo |
| Ars Pharmaceuticals Operations, INC. | $208.00 | 2025 | Neffy |
| Philips North America LLC | $196.43 | 2019-2021 | |
| Octapharma USA, INC. | $134.75 | 2019-2022 | |
| Lilly USA, LLC | $133.26 | 2024-2025 | Ebglyss, Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.33 | 2020-2025 | Spiriva Respimat, Jardiance |
| Hikma Pharmaceuticals USA | $112.06 | 2023-2025 | Ryaltris |
| Blueprint Medicines Corporation | $97.48 | 2023-2025 | Ayvakit |
| Eyevance Pharmaceuticals LLC | $75.85 | 2020-2021 | |
| Alk-Abello, INC | $75.49 | 2019-2021 | |
| Adma Biomanufacturing LLC | $62.34 | 2023-2024 | |
| Leo Pharma INC. | $60.39 | 2022-2024 | Adbry |
| Uswm, LLC | $52.04 | 2021 | |
| Cycle Pharmaceuticals INC | $50.92 | 2025 | Sajazir |
| Aimmune Therapeutics, INC. | $50.19 | 2020-2022 | |
| Incyte Corporation | $49.73 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $35.74 | 2025 | Nemluvio |
| Ionis Pharmaceuticals, INC. | $33.94 | 2025 | Dawnzera |
| Organon LLC | $33.16 | 2025 | Vtama |
| Phadia US INC. | $31.77 | 2020-2023 | Immunocap |
| Merck Sharp & Dohme LLC | $28.87 | 2021-2023 | |
| Shire North American Group INC | $28.26 | 2019 | |
| United Therapeutics Corporation | $26.22 | 2023 | Tyvaso |
| Kedrion Biopharma, INC. | $20.62 | 2025 | Rhogam Ultra-Filtered Plus, Koate, Gammaked |
| Circassia INC. | $17.18 | 2019 | |
| Arcutis Biotherapeutics, INC. | $16.97 | 2025 | Zoryve |
| Horizon Therapeutics Plc | $14.79 | 2020 | |
| Amarin Pharma, INC. | $14.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.